Viewing Study NCT03740893

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:12 AM
Ignite Modification Date: 2026-02-25 @ 7:28 PM
Study NCT ID: NCT03740893
Status: RECRUITING
Last Update Posted: 2025-08-11
First Post: 2018-10-05
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer
Sponsor: Institute of Cancer Research, United Kingdom
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Neoplasm View
None Triple Negative Breast Cancer (TNBC) View
None HRD View
Keywords:

Keywords

Keyword Brief Keyword Text View
None AZD6738 View
None Olaparib View
None Durvalumab View
None Window of opportunity View
None Triple negative breast cancer View
None Breast cancer View
None Homologous Repair Deficiency (HRD) View